ArticleOncoTargets and therapy2022

Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer.

Yawen Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.